Stockscreener 앱 받기
0.00
100.00%
-0.0941
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin Technologies Trades At A Discount As Risks Stack Up - Finimize
Boehringer Expands Eyecare Horizons With Palatin Collaboration - insights.citeline.com
Boehringer Ingelheim, Palatin Technologies to develop melanocortin receptor targeted treatment for... - Medical Dialogues
Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN
Boehringer and Palatin team up on retinal diseases research - The Pharma Letter
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - The Manila Times
Boehringer Ingelheim and Palatin Technologies to develop - GlobeNewswire
Boehringer Ingelheim Limited - Via Ritzau
Boehringer Ingelheim and Palatin Technologies, Inc. to Develop Potential First-In-Class Melanocortin Receptor Targeted Treatment for Patients with Retinal Diseases - MarketScreener
Palatin Technologies (PTNT) Stock Price, News & Analysis - MarketBeat
Palantin Technologies to enact 1-for-50 reverse stock split - MSN
Palantin Technologies Implements Reverse Stock Split to Meet NYSE Listing Requirements - AInvest
Palatin Technologies announces 1-for-50 reverse stock split - Investing.com India
Palatin Announces 1-for-50 Reverse Stock Split - The Malaysian Reserve
Palatin Technologies announces 1-for-50 reverse stock split By Investing.com - Investing.com Nigeria
Palatin Announces 1-For-50 Reverse Stock Split - Barchart.com
Palatin Technologies Stockholders Approve Key Governance Changes - TipRanks
Palatin Technologies shareholders approve reverse stock split and board elections - Investing.com
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - ADVFN Brasil
Why This French Biotech Stock Just Soared 586% In One Day - Barchart.com
Palatin Technologies reports efficacy of PL-7737 in obesity model - BioWorld MedTech
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - The Malaysian Reserve
Palatin announces positive preclinical efficacy data for oral MC4R agonist PL7737 in animal model of obesity - MarketScreener
Breakthrough Oral Weight Loss Drug Achieves 15% Reduction When Combined with Tirzepatide in Just 4 Days - Stock Titan
Palatin Technologies receives NYSE American delisting notice, appeals decision By Investing.com - Investing.com Nigeria
Palatin Technologies receives NYSE American delisting notice, appeals decision - Investing.com Australia
Palatin Technologies Announces Closing of Reduced Public Offering (PR Newswire) - Aktiellt
Palatin Technologies Executives Make Massive Stock Purchases! - TipRanks
Palatin Technologies Raises $340K in Private Placement - TipRanks
Palatin Technologies, Inc. announced that it expects to receive $0.34 million in funding - MarketScreener
Palatin Technologies (PALI) Teams Up with Key Managers for Inves - GuruFocus
Palatin Technologies (PALI) Teams Up with Key Managers for Investment Strategy | PALI Stock News - GuruFocus
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com UK
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
1.33%
1.34%
자본화:
|
볼륨(24시간):